ArriVent BioPharma, Inc. AVBP Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s financing cash flow?
- ArriVent BioPharma, Inc. (AVBP) reported financing cash flow of $54.87M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s financing cash flow changed year-over-year?
- ArriVent BioPharma, Inc.'s financing cash flow increased by 711.9% year-over-year, from $6.76M to $54.87M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.